Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health outcomes, today announced a new grant award from the Bill & Melinda Gates Foundation.
This collaboration focuses on enabling complex decision-making by combining results from point-of-care tests with smartphone data – creating essential opportunities in countries with limited access to sophisticated laboratory testing. This work will explore the feasibility of integrating wireless technologies intended to simplify field-based workflows and to reduce dependence on wired power sources into OmniVeritaM – the smartphone-enabled portable diagnostic platform being developed by Biological Dynamics. The ultimate objective of the portable is to enable affordable, user-friendly, and sensitive diagnostic testing for high-burden conditions that can be successfully deployed to resource-poor settings on a global scale.
“We are thrilled to expand our engagement with the Bill & Melinda Gates Foundation, beyond our current work in tuberculosis testing. With the sensitivity and scalability of our platform, we can empower healthcare workers by providing actionable, affordable, and timely clinical-grade diagnostic information by putting diagnostics at their fingertips,” said Raj Krishnan, Ph.D., CEO of Biological Dynamics. “We believe in the potential of this collaboration to bring much-needed real-time health decision making to underserved populations in low- and middle-income countries.”
The technology is powered by Biological Dynamics’ novel isolation platform, Verita™, which enables the isolation of circulating biomarkers such as cell-free DNA and exosomes from whole blood, serum, and plasma without the need to pre-process samples. The Company is currently applying the cutting-edge isolation capabilities of Verita™ to develop the next generation of lab and point-of-care tests for the early detection and treatment response monitoring of cancer.
About Biological Dynamics
Biological Dynamics, Inc. is an innovative diagnostic company committed to improving global health outcomes by empowering healthcare communities with accessible diagnostics. Biological Dynamics’ proprietary technology platform, Verita™, isolates nanoparticles and macromolecules directly from whole blood, serum, or plasma without the need for pre-processing samples. The Company is developing a portfolio of novel oncology and infectious disease products designed to enable early detection and individualized treatment response monitoring. In addition to lab-focused products, Biological Dynamics is also developing a smartphone-enabled portable version of the platform with the goal of bringing blood-based DNA testing into the home. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.